Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) with or without chemotherapy represent first-line standard of care for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. The most appropriate second-line therapy after failing immunochemotherapy remains an open question. Nintedanib, an oral triple angiokinase inhibitor that targets the vascular endothelial growth factor receptor, fibroblast growth factor receptor, and, platelet-derived growth factor receptor, in combination with docetaxel, is approved for treatment of advanced NSCLC (adenocarcinoma histology) following progression on first-line chemotherapy.

Methods

VARGADO (NCT02392455) is an ongoing, prospective, non-interventional study investigating the efficacy and safety of nint

SUBMITTER: Grohe C 

PROVIDER: S-EPMC9641040 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature